JP2024510606A5 - - Google Patents
Info
- Publication number
- JP2024510606A5 JP2024510606A5 JP2023555666A JP2023555666A JP2024510606A5 JP 2024510606 A5 JP2024510606 A5 JP 2024510606A5 JP 2023555666 A JP2023555666 A JP 2023555666A JP 2023555666 A JP2023555666 A JP 2023555666A JP 2024510606 A5 JP2024510606 A5 JP 2024510606A5
- Authority
- JP
- Japan
- Prior art keywords
- diazabicyclo
- chloro
- methoxy
- octan
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160431P | 2021-03-12 | 2021-03-12 | |
| US63/160,431 | 2021-03-12 | ||
| US202163173021P | 2021-04-09 | 2021-04-09 | |
| US63/173,021 | 2021-04-09 | ||
| US202163220386P | 2021-07-09 | 2021-07-09 | |
| US63/220,386 | 2021-07-09 | ||
| US202163236497P | 2021-08-24 | 2021-08-24 | |
| US63/236,497 | 2021-08-24 | ||
| PCT/US2022/020239 WO2022192794A1 (en) | 2021-03-12 | 2022-03-14 | Kras g12d inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510606A JP2024510606A (ja) | 2024-03-08 |
| JP2024510606A5 true JP2024510606A5 (https=) | 2025-03-24 |
Family
ID=81213567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555666A Pending JP2024510606A (ja) | 2021-03-12 | 2022-03-14 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317769A1 (https=) |
| EP (1) | EP4305038B1 (https=) |
| JP (1) | JP2024510606A (https=) |
| KR (1) | KR20230169967A (https=) |
| AU (1) | AU2022232523A1 (https=) |
| BR (1) | BR112023017763A2 (https=) |
| CA (1) | CA3210053A1 (https=) |
| ES (1) | ES3013592T3 (https=) |
| IL (1) | IL305568A (https=) |
| MX (1) | MX2023010430A (https=) |
| WO (1) | WO2022192794A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| CN115181106B (zh) * | 2021-04-07 | 2024-04-05 | 药雅科技(上海)有限公司 | 喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用 |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| EP4363412A4 (en) * | 2021-06-30 | 2025-05-14 | Dana-Farber Cancer Institute, Inc. | Small-molecule inhibitors of the KRAS G12D mutant |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| EP4371991A4 (en) * | 2022-01-21 | 2025-02-26 | Usynova Pharmaceuticals Ltd. | Benzopyrimidine compounds and use thereof |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN118344386A (zh) * | 2023-01-13 | 2024-07-16 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202416976A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商南京明德新藥研發有限公司 | 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物 |
| WO2024061365A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都奥睿药业有限公司 | 嘧啶并环类化合物及其制备方法与用途 |
| JP2025534419A (ja) * | 2022-09-30 | 2025-10-15 | トラスヴェダ リミテッド | Ｋｒａｓ変異腫瘍に対する抗腫瘍活性を有する化合物 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| JP2025536369A (ja) | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| CN117263959A (zh) * | 2022-10-24 | 2023-12-22 | 药雅科技(上海)有限公司 | 芳香类kras突变蛋白抑制剂的制备及其应用 |
| WO2024092420A1 (zh) * | 2022-10-31 | 2024-05-10 | 上海皓元医药股份有限公司 | 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024186680A1 (en) * | 2023-03-03 | 2024-09-12 | Frontier Medicines Corporation | Methods for preparing pyrrolizidine compounds |
| CN117903192A (zh) * | 2023-03-12 | 2024-04-19 | 上海相辉医药科技有限公司 | 一种3-甲氧基异喹啉化合物中间体的制备方法 |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| WO2024215862A2 (en) * | 2023-04-12 | 2024-10-17 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| WO2024227091A1 (en) * | 2023-04-26 | 2024-10-31 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Diazabicyclooctane inhibitors of kras (g12d) and uses |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121100120A (zh) * | 2023-05-07 | 2025-12-09 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR102738924B1 (ko) * | 2023-12-26 | 2024-12-06 | 주식회사 베노바이오 | Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2021031952A1 (zh) * | 2019-08-16 | 2021-02-25 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| KR20230136636A (ko) * | 2021-02-09 | 2023-09-26 | 메드샤인 디스커버리 아이엔씨. | 피리미딘 방향족 환 화합물 |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
-
2022
- 2022-03-14 MX MX2023010430A patent/MX2023010430A/es unknown
- 2022-03-14 IL IL305568A patent/IL305568A/en unknown
- 2022-03-14 US US18/550,234 patent/US20240317769A1/en active Pending
- 2022-03-14 EP EP22714667.7A patent/EP4305038B1/en active Active
- 2022-03-14 ES ES22714667T patent/ES3013592T3/es active Active
- 2022-03-14 BR BR112023017763A patent/BR112023017763A2/pt unknown
- 2022-03-14 JP JP2023555666A patent/JP2024510606A/ja active Pending
- 2022-03-14 AU AU2022232523A patent/AU2022232523A1/en active Pending
- 2022-03-14 CA CA3210053A patent/CA3210053A1/en active Pending
- 2022-03-14 KR KR1020237034229A patent/KR20230169967A/ko active Pending
- 2022-03-14 WO PCT/US2022/020239 patent/WO2022192794A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510606A5 (https=) | ||
| JP2024510207A5 (https=) | ||
| JP7313354B2 (ja) | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 | |
| CN112166110B (zh) | Shp2磷酸酶抑制剂及其使用方法 | |
| CN105294683B (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| KR20230167386A (ko) | 옥사제핀 화합물 및 암 치료에서의 이의 사용 | |
| ES2805087T3 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la cinasa RET | |
| JP2025533831A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質のテザー型複素環式阻害剤及びその使用 | |
| DK2536730T3 (en) | Pyrrolopyrimidinforbindelser as CDK4 / 6 inhibitors | |
| JP2024532735A5 (https=) | ||
| JP2024532734A5 (https=) | ||
| ES2616679T3 (es) | Nuevos derivados de indolizina, procedimiento para su preparación y composiciones farmacéuticas que los contienen para el tratamiento del cáncer | |
| HRP20240293T1 (hr) | Derivati kinazolina kao protutumorska sredstva | |
| TW202529806A (zh) | 包含ｋｒａｓ ｇ１２ｄ抑制劑及ｅｇｆｒ抑制劑之組合療法 | |
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| JP2017531672A5 (https=) | ||
| JP2015524798A5 (https=) | ||
| RU2017117248A (ru) | Этил-n-boc-пиперидинил-пиразоло-пиридоны в качестве ингибиторов янус-киназы | |
| RU2020100930A (ru) | Фармацевтические соединения | |
| JP2018522929A5 (https=) | ||
| CA3174207A1 (en) | Egfr degraders to treat cancer metastasized to the brain or cns | |
| EP3782997A1 (en) | Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases | |
| RU2018117503A (ru) | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ | |
| JP2024521818A5 (https=) |